ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
ABY-035-204 is a clinical study to assess the efficacy of IL-17 blocker ABY-035 in ankylosing spondylitis(AS). The primary objective is to estimate the relationship between different dose regimens of ABY-035 and clinical response as assessed by Assessment of Spondyloarthritis International Society 40 (ASAS40) response at Week 16 in subjects with active AS.
Epistemonikos ID: 8d413bd261ee1c33b90ab56d6eeb3b2fb7cc9365
First added on: May 08, 2024